MedTrace Logo

SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)

NCT04344184 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-04-04

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety of a 96-hour intravenous vitamin C infusion protocol (50 mg/kg every 6 hours) in patients with hypoxemia and suspected COVID-19.

Conditions

  • COVID-19
  • Lung Injury, Acute
  • Kidney Injury

Interventions

DRUG

L-ascorbic acid

50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours

OTHER

Placebo

Dextrose 5% Water

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Alpha (Berry) A Fowler, III, MD · Virginia Commonwealth University

  • Brian Davis, MD · Hunter Holmes McGuire VA Medical Center - Richmond, VA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-18
Primary Completion
2022-06-10
Completion
2022-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04344184 on ClinicalTrials.gov